Originally approved in 1996 for use in the United States after the positive National Institute of Neurological Disorders and Stroke (NINDS) trial [4], thrombolysis with intravenous tissue plasminogen activator (IV-tPA) is considered to be the standard of care for eligible patients suffering from acute ischemic stroke [4]. The recommended window for IV-tPA treatment is within 3, or in some cases 4.5, hours after the onset of stoke [5, 6]. This evidence concerns the gene PLAT and Stroke.